Antifibrotic Therapy in Nonalcoholic Steatohepatitis: Time for a Human-Centric Approach

The authors discuss why antifibrotic effects observed in NASH pharmacotherapy trials have been underwhelming and outline potential approaches to improve the likelihood of future clinical success.